Provepharm signs license agreement with Daiichi Sankyo to provide methylthioninium chloride Proveblue solution for injection to Japan
Daiichi Sankyo will resolve the unmet need for an approved methylthioninium chloride injectable drug in Japan
01-Dec-2011
- France
Under this agreement Provepharm grants Daiichi Sankyo exclusive rights to methylthioninium chloride Proveblue solution for injection in Japan. Daiichi Sankyo will be responsible for the submission of a marketing authorization application and for all commercial activities relating to the product in this country. Commercial terms of the deal were not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.